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Allogeneic hematopoietic cell transplantation (HCT) following
non-myeloablative conditioning has been an effective treatment
for many patients with malignancies. This approach relies on
graft-versus-tumor effects for tumor eradication.1 Following non-
myeloablative conditioning, acute graft-versus-host disease
(GVHD) has not been associated with significant graft-versus-
tumor effects, but has rather been associated with a high risk of
non-relapse mortality,1 indicating that efforts aimed at decreas-
ing the incidence of acute GVHD are needed. On the basis of
previous studies suggesting that CD8 depletion of the graft could
reduce the incidence of acute GVHD without apparently
impairing graft-versus-tumor effects,2 and that CD8-depleted
donor lymphocyte infusion (DLI) induced strong graft-versus-
tumor effects with a low incidence of acute GVHD (o10%),3
we designed a phase II prospective randomized trial evaluating
the impact of CD8 depletion of peripheral blood stem cells
(PBSCs) on HCT outcomes after non-myeloablative condition-
ing. The protocol was approved by the local Ethics Committee,
and written informed consent was obtained from each patient.
The trial started in March 2002, and the study was retro-
spectively registered in ClinicalTrials.gov (protocol no.
NCT00693927) in June 2008. Immune recovery in these
patients has been previously reported.4
After being stratified for donor type, patients were randomized
1:1 between the ‘unmanipulated’ (n¼ 28) and ‘CD8-depleted’
(n¼ 25) arms. Conditioning regimen consisted of 2 Gy total
body irradiation with or without fludarabine (90 mg/m2).
Postgrafting immunosuppression included cyclosporine plus
mycophenolate mofetil. Clinical management and chimerism
analyses were performed as reported earlier.4 In total, 23
patients received DLI for disease persistence or progression (1 in
the unmanipulated group and 2 in the CD8-depleted group), or
poor T-cell chimerism with or without persistent disease (12 in
the unmanipulated group and 8 in the CD8-depleted group),
including 5 patients in the unmanipulated group and 4 patients
in the CD8-depleted group who received DLI preceded by 2 Gy
total body irradiation as part of a prospective study evaluating
this strategy to prevent graft rejection in patients with low donor
T-cell chimerism levels. Results were analyzed as of 29 May
2008. Survival and progression-free survival were estimated
using the Kaplan–Meier method. The incidences of acute and
chronic GVHD, relapse and non-relapse mortality were
calculated using cumulative incidence estimates as reported
earlier.1 Patients who received DLI were censured for acute
GVHD at the time of DLI, patients with graft rejection were
censured at the time of graft rejection for GVHD analyses.
Multivariate logistic regression models were fitted with the SAS
LOGISTIC procedure (SAS Institute, Cary, NC, USA) for graft
rejection and GVHD. Multivariate Cox models were fitted for
analyzing progression-free and overall survivals, non-relapse
mortality and relapse risk.
In total, 53 patients transplanted between March 2002 and
May 2004 were included (Table 1). Scheduled CD8 depletion
was not performed in three patients with number of CD34þ
cells collected o4.0 106 cells/kg. These patients received
unmanipulated grafts, but were nevertheless included in the
CD8-depleted group (intent-to-treat analysis). Median follow-up
for surviving patients was 56 months. Median donor T-cell
chimerism levels in CD8-depleted versus unmanipulated
recipients were 46% (range, 0.2–100) versus 71% (range,
15–100) on day 28 (P¼ 0.035), and 93% (range, 49–100) versus
84% (range, 50–100) on day 365 (P¼ 0.9), respectively.
Confirming previous observations,6 four of seven patients with
day 28 T-cell chimerism levels between 5 and 30% versus none
of the 38 patients with 430% day 28 donor T-cell chimerism
levels (P¼ 0.0002) experienced graft rejection. Eight (four
initial and four late) graft rejections were observed in the
CD8-depleted group (including one of the three patients with
low CD34þ cell count given unmanipulated PBSC) versus none
in the unmanipulated group (P¼ 0.001). In multivariate analysis,
human leukocyte antigen (HLA)-mismatched donor was asso-
ciated with a trend for higher risk of graft rejection (hazard ratio
(HR) 4.1; P¼ 0.09), whereas the association between study
group and graft rejection was present, although not statistically
significant (HR 1.9; P¼ 0.32). In agreement with our results, a
randomized study including 38 patients given unmanipulated
or CD8-depleted marrows from HLA-identical siblings following
myeloablative conditioning suggested a higher risk of graft
failure (2 of 19 patients versus 0 of 19 patients) following CD8
depletion of the grafts, although the difference was not
statistically significant.2
Acute GVHD of grades II–IV was seen in eight (32%), one
(4%) and 0 (0%) in the CD8-depleted group versus in seven
(25%), one (4%) and four (14%) in the unmanipulated group,
respectively. The 180-day cumulative incidences of grades II–IV
and III–IV acute GVHD were 37.6 and 4.0% in the CD8-
depleted group versus 43.2% (P¼ 0.7) and 18.1% (P¼ 0.13) in
the unmanipulated group, respectively. The 2-year cumulative
incidence of chronic GVHD of National Institutes of Health
(NIH) grades II–III was 29% in the CD8-depleted group versus
57% in the unmanipulated group, respectively (P¼ 0.09).
Possible explanations for the similar incidence of GVHD in
the two groups could be the limited number of patients in each
arm limiting the power to detect statistically significant
differences, or that the number of CD8þ T cells infused does
not correlate with occurrence of acute GVHD after non-
myeloablative conditioning. In support of the latter hypothesis,
two retrospective studies failed to demonstrate an association
between the numbers of CD8þ T cells transplanted and acute
GVHD incidence.7,8 However, it should be stressed that none of
these studies used CD8 depletion of PBSC, and the median
number of CD8þ T cells infused in the current CD8-depleted
group was 2.5–5 times lower than the minimal number of
transfused CD8þ T cells in these studies.7,8 In contrast to
our results, CD8 depletion of the grafts has been associated
with decreased incidence of grade II–IV acute GVHD in a
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randomized study including 38 patients given marrows from
HLA-identical siblings following myeloablative conditioning
and cyclosporine alone as GVHD prophylaxis (20 versus 80%,
Po0.01).2 Obviously, there were many discrepancies between
the two randomized studies, such as the intensity of the
conditioning, the stem cell source and the postgrafting
immunosuppression, that could all have had an impact on the
efficacy of CD8 depletion for preventing acute GVHD.
The 100-day probabilities of septicemia (except those
caused by coagulase-negative staphylococcus), cytomegalo-
virus infection and fungal infection were 22, 54 and 4%,
respectively in the unmanipulated group, versus 26% (P¼ 0.8),
59% (P¼ 1.0) and 5% (P¼ 0.9), respectively, in the CD8-
depleted group.
The 5-year cumulative incidence of relapse/progression was
46% in the CD8-depleted group versus 47% in the unmanipu-
lated group (P¼ 0.7). In multivariate analysis, higher disease
risk (see Table 1) was associated with a higher risk of relapse
(HR 2.2; P¼ 0.004). Here, 100-day and 5-year non-relapse
mortalities were 12 and 32% in the CD8-depleted group versus
4 and 26% in the unmanipulated group (P¼ 0.8), respectively.
In multivariate analysis, patients given HLA-mismatched grafts
had higher risk of non-relapse mortality than those given grafts
from HLA-identical siblings (P¼ 0.028) or from 10/10 HLA-
allele-matched unrelated donors (P¼ 0.083). Five-year progres-
sion-free and overall survival were 23 and 45% in the CD8-
depleted group versus 28% (P¼ 0.5) and 48% (P¼ 0.85;
Figure 1a) in the unmanipulated group, respectively. In multi-
variate analysis, patients given HLA-mismatched grafts had a
worse survival than those given grafts from HLA-identical sibling
(HR 2.6; P¼ 0.041) or from 10/10 HLA-allele-matched un-
related donors (HR 1.8; P¼ 0.26; Figure 1b).
In summary, CD8 depletion of PBSC failed to reduce the
incidence of acute GVHD but increased the risk of graft
rejection after non-myeloablative conditioning. Furthermore,
HLA-mismatched PBSC recipients had higher risk of graft
rejection, higher risk of non-relapse mortality and shorter
survival than those given PBSC from HLA-identical siblings.
Table 1 Characteristics of patients
CD8-depleted a PBSC Unmanipulated PBSC
Number of patients 25 28
Median age (range) (years) 57 (36–69) 57 (41–65)
Gender (male/female), no. of patients 13/12 19/9
Disease at transplantation; no. of patients
AML in CR/4CR 0/0 2/1
CML in AP 2 0
CLL in PR/refractory 1/4 0/1
NHL in CR/in PR/4PR 4/2/1 6/1/1
MDSb RA/RAEB/RAEB-t 6/1/1 2/3/1
MM in CR/not in CR 0/1 2/5
Myeloproliferative disorder 2 1
Metastatic RCC 0 2
Disease riskc: low/standard/high; no. of patients 7/6/12 12/6/10
Donor type; no. of patients
HLA-identical sibling/child 10/1 12/0
10/10 HLA-allele-matched or 1 HLA-allele-mismatched URD 6 8
2 HLA-allele-mismatched URD 1 0
1 HLA antigen-mismatched URD 5 6
41 HLA antigen-mismatched donor 2 2
Conditioning regimen; no. of patients
2 Gy TBI 6 7
2 Gy TBI+fludarabine 19 21
No. of cells transplanted (106/kg); median (range)
CD34 3.6 (0.7–12.2) 4.2 (0.8–20.2)
CD3 111 (56–500) 314 (80–631)
CD8 4.6 (0.4–195) 130 (42–272)
Abbreviations: AML, acute myeloid leukemia; AP, accelerated phase; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CR,
complete remission; HCT, hematopoietic cell transplantation; HLA, human leukocyte antigen; MDS, myelodysplastic syndrome; MM, multiple
myeloma; NHL, non-Hodgkin lymphoma; PR, partial remission; RA, refractory anemia; RAEB, refractory anemia with blast excess; RAEB-t,
refractory anemia with blast excess in transformation; RCC, renal cell carcinoma; TBI, total body irradiation; URD, 10/10 HLA-allele-matched
unrelated donor.
aCD8 depletion was carried out using the CD8-HDM (high-density microparticles, BB-IDE 6969, generously given by BioTransplant Inc.,
Charlestown, MA, USA) device, as recommended by the manufacturer.
bStatus at HCT.
cAs defined by Kahl et al.,5 low risks include CLL in CR, low-grade NHL, MM in CR, mantle cell lymphoma, myeloproliferative disease, high-grade
NHL in CR and acute lymphoblastic leukemia in first CR; standard risks include CLL or MM not in CR, MDS refractory anemia/refractory anemia
ringed sideroblasts, AML in CR, and CML in first chronic phase; and high risks include MDS refractory anemia with excess of blasts (RAEB)/RAEB
in transformation (RAEB-t), AML after MDS or AML not in CR, high-grade NHL not in CR, Hodgkin lymphoma, MDS after chemotherapy, CML
in second CP or accelerated phase/blast crisis, acute lymphoblastic leukemia in second or later CR, chronic myelomonocytic leukemia (CMML),
and RCC.
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Figure 1 (a) Overall survival in CD8-depleted (broken lines) and
unmanipulated (solid lines) peripheral blood stem cell (PBSC)
recipients. (b) Overall survival according to donor type (Sibl, HLA-
identical sibling; URD, 10/10 HLA-allele-matched unrelated donor;
MM, HLA-mismatched donor).
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